Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia
Authors:
Open Access
- 28 February 2019
- journal article
- research article
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 104 (11) , 2225-2240
Abstract
Induction therapy for patients with acute myeloid leukemia has remained largely unchanged for over 40 years, while overall survival rates remain unacceptably low, highlighting the need for new therapies. The PI3K/Akt pathway is constitutively active in the majority of acute myeloid leukemia patients. Given that histone deacetylase inhibitors have been shown to synergize with PI3K inhibitors in preclinical acute myeloid leukemia models, we investigated the novel dual acting PI3K and histone deacetylase inhibitor CUDC-907 in acute myeloid leukemia cells both in vitro and in vivo. We demonstrate that CUDC-907 induces apoptosis in acute myeloid leukemia cell lines and primary patient samples and shows in vivo efficacy in an acute myeloid leukemia cell line-derived xenograft mouse model. CUDC-907-induced apoptosis was partially dependent on Mcl-1, Bim, and c-Myc. CUDC-907 induces DNA damage in acute myeloid leukemia cells while sparing normal hematopoietic cells. Downregulation of CHK1, Wee1, and RRM1, and induction of DNA damage also contributed to CUDC-907-induced apoptosis of acute myeloid leukemia cells. In addition, CUDC-907 treatment decreases leukemia progenitor cells in primary acute myeloid leukemia samples ex vivo, while also sparing normal hematopoietic progenitor cells. These findings support the clinical development of CUDC-907 for the treatment of acute myeloid leukemia.Keywords
This publication has 43 references indexed in Scilit:
- Suppression of Feedback Loops Mediated by PI3K/mTOR Induces Multiple Overactivation of Compensatory Pathways: An Unintended Consequence Leading to Drug ResistanceMolecular Cancer Therapeutics, 2014
- The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensationTrends in Biochemical Sciences, 2011
- Bim Upregulation by Histone Deacetylase Inhibitors Mediates Interactions with the Bcl-2 Antagonist ABT-737: Evidence for Distinct Roles for Bcl-2, Bcl-xL, and Mcl-1Molecular and Cellular Biology, 2009
- Apoptosis induced by histone deacetylase inhibitors in leukemic cells is mediated by Bim and NoxaLeukemia, 2007
- Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancerNature Reviews Cancer, 2006
- Superior Activity of the Combination of Histone Deacetylase Inhibitor LAQ824 and the FLT-3 Kinase Inhibitor PKC412 against Human Acute Myelogenous Leukemia Cells with Mutant FLT-3Clinical Cancer Research, 2004
- Inhibition of PI-3 kinase sensitizes human leukemic cells to histone deacetylase inhibitor-mediated apoptosis through p44/42 MAP kinase inactivation and abrogation of p21CIP1/WAF1 induction rather than AKT inhibitionOncogene, 2003
- Survival of acute myeloid leukemia cells requires PI3 kinase activationBlood, 2003
- Activation of the ERK1/2 Signaling Pathway Promotes Phosphorylation and Proteasome-dependent Degradation of the BH3-only Protein, BimJournal of Biological Chemistry, 2003
- Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukemia: its significance as a prognostic variableLeukemia, 2003